HR 1117 · in committee · significant
Responsibility in Drug Advertising Act of 2025
- healthcare
What this bill does
- The bill bans drug companies from advertising new medications directly to consumers for three years after FDA approval.
- Pharmaceutical companies and consumers seeking information about newly approved drugs are affected by this advertising restriction.
- The FDA can grant early exceptions in year three if public health benefits exist, or extend bans beyond three years if safety issues emerge.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How would a three-year advertising ban affect patients' ability to learn about newly approved treatment options for their conditions?
- 02
What evidence suggests that delaying direct-to-consumer drug advertising improves medication safety or reduces inappropriate prescribing?
- 03
Which public health scenarios would justify the FDA granting early exceptions to the advertising ban during year three?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · D-CT-3
Rosa L. DeLauro
Citizen cosponsors
0
In Congress
0/ 435
House Reps cosponsoring
Introduced 2025-02-07
Legislative timeline
2025-02-07 · house · IntroReferral
Referred to the House Committee on Energy and Commerce.
2025-02-07 · IntroReferral
Introduced in House
2025-02-07 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.